Renal Cell Carcinoma Highlights From ASCO GU 2024 Renal Cell Carcinoma Highlights From ASCO GU 2024
Key data in renal cell carcinoma from ASCO GU 2024 includes pembrolizumab in early higher-risk RCC, belzutifan in advanced disease, and developments in quality-of-life tools.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 16, 2024 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

Advancements in RCC Treatment and Cure Rates Advancements in RCC Treatment and Cure Rates
Dr Katy Beckermann expresses optimism for the future of the treatment of renal cell carcinoma through the safe combination of new therapeutic agents.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 16, 2024 Category: Consumer Health News Tags: None MDAngle Source Type: news

' Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer'Breakthrough': Adjuvant Pembro Ups Survival in Renal Cancer
KEYNOTE-564 is the first trial to demonstrate an overall survival benefit with adjuvant immunotherapy in patients with clear cell renal cell carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

Pembrolizumab Shows Survival Benefit for Patients With Renal Cancer
WEDNESDAY, Jan. 31, 2024 -- For patients with clear-cell renal cell carcinoma (ccRCC), overall survival (OS) is improved for those receiving pembrolizumab versus placebo at a median follow-up of about 57 months, according to a study presented at the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2024 Category: Pharmaceuticals Source Type: news

Subcutaneous Nivolumab as Effective as IV for Renal Cell Carcinoma -- With Much Faster Treatment Time
Subcutaneous injection of the immunotherapy nivolumab (brand name Opdivo) is noninferior to intravenous delivery and dramatically reduces treatment time in patients with renal cell carcinoma, as reported by Dr. Saby George of Roswell Park Comprehensive Cancer Center today at the 2024... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - January 29, 2024 Category: Pharmaceuticals Tags: TRI Source Type: news

A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma
(MedPage Today) -- SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) boosted overall survival (OS) in post-surgical patients with clear cell renal cell carcinoma (RCC) at risk for recurrence, according to KEYNOTE-564 findings. Patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news

Telix submits PET tracer for FDA review
Telix Pharmaceuticals has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its clear cell renal cell carcinoma PET radiotracer TLX250-CDx (Zircaix).The PET tracer has been granted a rolling review process under the FDA’s Breakthrough Therapy designation, which will enable a progressive submission and review of required modules in a timeframe agreed upon with the FDA, the company said. It has also requested priority review.In addition, Telix said it has opened an expanded access program in the U.S. and a named-patient program in Europe to allow access to Zircaix outside of...
Source: AuntMinnie.com Headlines - December 19, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news

Belzutifan Approved for Advanced Renal Cell Carcinoma Belzutifan Approved for Advanced Renal Cell Carcinoma
The FDA approval makes belzutifan the first agent specifically indicated for renal cell carcinoma that has progressed after checkpoint inhibition and a VEGF-TKI.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news

FDA Approves Belzutifan for Advanced Renal Cell Carcinoma
(MedPage Today) -- The FDA approved belzutifan (Welireg) for previously treated advanced renal cell carcinoma (RCC), the agency announced on Thursday. Belzutifan is indicated for RCC patients with disease progression after a PD-1/L1 checkpoint... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 15, 2023 Category: American Health Source Type: news

FDA Approves Merck ’s Welireg (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI
RAHWAY, N.J.--(BUSINESS WIRE) December 14, 2023 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Welireg, an oral hypoxia-inducible factor-2... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 14, 2023 Category: Drugs & Pharmacology Source Type: news

FDA approves belzutifan for advanced renal cell carcinoma
On December 14, 2023, the Food and Drug Administration approved belzutifan (Welireg, Merck& Co., Inc.) for patients with advanced renal cell carcinoma (RCC). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 14, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Telix highlights first patient dosed with new renal cancer PET agent
Telix Pharmaceuticals is highlighting that the first patient has been dosed with the company's TLX250-CDx (Zr-89 DFO-girentuximab) for clear cell renal cell carcinoma, the most common and aggressive form of kidney cancer.The patient program is being conducted at Radboud University Medical Centre in Nijmegen, the Netherlands, and follows the completion of Telix's phase III ZIRCON study (Zirconium in Renal Cancer Oncology) which reported positive results, according to the firm.Telix is moving forward toward completing a Biologics License Application submission for TLX250-CDx with the U.S. Food and Drug Administration, it...
Source: AuntMinnie.com Headlines - December 4, 2023 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Subspecialties Nuclear Radiology Source Type: news

AI algorithm helps determine status of small renal lesions
CHICAGO -- A deep-learning AI algorithm designed to determine the malignancy status of renal lesions less than 4 cm could reduce overtreatment and undertreatment of kidney cancer, according to research presented November 26 at RSNA 2023.The AI functions by taking a preoperative CT scan as input, localizes the tumor region by segmenting it, and then predicts the probability of malignancy in a fully automated fashion, according to Aakanksha Rana, PhD, of Johnson & Johnson in New Brunswick, NJ.“The outcome was good given our small dataset,” Rana said, adding that there is much work to be done. “It’s very surprising to...
Source: AuntMinnie.com Headlines - November 26, 2023 Category: Radiology Authors: Liz Carey Tags: Resources Conference RSNA 2023 Source Type: news

Treatment of Favorable-Risk Advanced Renal Cell Carcinoma Treatment of Favorable-Risk Advanced Renal Cell Carcinoma
Experts discuss strategies for treating patients with favorable-risk advanced renal cell carcinoma in light of IMDC guidelines and recent prospective studies.Medscape (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 17, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news

'We're Not There Yet': CAR T-Cell Therapy for Renal Cell Carcinoma
(MedPage Today) -- NASHVILLE, Tenn. -- Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - November 16, 2023 Category: Hematology Source Type: news